Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
Go back to Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer| VERASTEM SHS (NASDAQ: VSTM) | Delayed: 6.18 +0.29 (4.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.89 | 52 Week High | $2.43 | |||
| Open | $5.87 | 52 Week Low | $1.05 | |||
| Day High | $6.31 | P/E | N/A | |||
| Day Low | $5.75 | EPS | $-1.79 | |||
| Volume | 2,193,671 | |||||
